Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:PDPNASDAQ:RENENYSE:UPCNASDAQ:VRDN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumePDPInvesco Dorsey Wright Momentum ETF$109.09+1.4%$104.92$86.41▼$117.67$1.68B1.0222,290 shs34,894 shsRENECartesian Growth Co. II$11.75$11.78$11.28▼$11.95$254.05M-0.01101,479 shs1 shsUPCUniverse Pharmaceuticals$3.85+0.8%$4.51$2.51▼$2,592.00$166K1.43175,870 shs3,420 shsVRDNViridian Therapeutics$15.59+2.3%$14.07$9.90▼$27.20$1.27B0.391.15 million shs396,663 shs10 Stocks Set to Soar in Summer 2025Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformancePDPInvesco Dorsey Wright Momentum ETF0.00%+1.27%+1.94%+20.54%+10.50%RENECartesian Growth Co. II0.00%0.00%0.00%-0.89%+4.17%UPCUniverse Pharmaceuticals0.00%+5.48%-10.26%+24.60%-99.81%VRDNViridian Therapeutics0.00%+8.76%+6.16%+32.30%+26.50%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationPDPInvesco Dorsey Wright Momentum ETFN/AN/AN/AN/AN/AN/AN/AN/ARENECartesian Growth Co. IIN/AN/AN/AN/AN/AN/AN/AN/AUPCUniverse PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/AVRDNViridian Therapeutics1.7675 of 5 stars4.50.00.00.02.10.00.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PricePDPInvesco Dorsey Wright Momentum ETF 2.68Moderate Buy$109.09N/ARENECartesian Growth Co. II 0.00N/AN/AN/AUPCUniverse Pharmaceuticals 0.00N/AN/AN/AVRDNViridian Therapeutics 2.90Moderate Buy$37.56140.97% UpsideCurrent Analyst Ratings BreakdownLatest UPC, VRDN, OBD, PDP, and RENE Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/20/2025VRDNViridian TherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$36.00 ➝ $36.005/7/2025VRDNViridian TherapeuticsThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$31.00 ➝ $27.005/7/2025VRDNViridian TherapeuticsRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$46.00 ➝ $45.005/7/2025VRDNViridian TherapeuticsJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetMarket Outperform ➝ Market Outperform$42.00 ➝ $38.005/7/2025VRDNViridian TherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$38.00 ➝ $36.004/23/2025VRDNViridian TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$34.00 ➝ $34.00(Data available from 7/7/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookPDPInvesco Dorsey Wright Momentum ETFN/AN/AN/AN/AN/AN/ARENECartesian Growth Co. IIN/AN/A$0.40 per share29.45($0.64) per shareN/AUPCUniverse Pharmaceuticals$23.02M0.01N/AN/A$163.50 per share0.02VRDNViridian Therapeutics$300K4,238.60N/AN/A$6.09 per share2.56Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DatePDPInvesco Dorsey Wright Momentum ETFN/AN/A27.88∞N/AN/AN/AN/AN/ARENECartesian Growth Co. II$11.44MN/A0.00∞N/AN/A-51.08%5.43%8/13/2025 (Estimated)UPCUniverse Pharmaceuticals-$6.16MN/A0.00∞N/AN/AN/AN/AN/AVRDNViridian Therapeutics-$269.95M-$3.85N/AN/AN/A-102,092.39%-70.61%-44.67%8/14/2025 (Estimated)Latest UPC, VRDN, OBD, PDP, and RENE EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/6/2025Q1 2025VRDNViridian Therapeutics-$0.95-$0.87+$0.08-$0.87$0.16 million$0.07 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthPDPInvesco Dorsey Wright Momentum ETF$0.220.20%N/AN/AN/ARENECartesian Growth Co. IIN/AN/AN/AN/AN/AUPCUniverse PharmaceuticalsN/AN/AN/AN/AN/AVRDNViridian TherapeuticsN/AN/AN/AN/AN/ALatest UPC, VRDN, OBD, PDP, and RENE DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date6/23/2025PDPInvesco Dorsey Wright Momentum ETFQuarterly$0.04290.16%6/23/20256/23/20256/27/2025(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioPDPInvesco Dorsey Wright Momentum ETFN/AN/AN/ARENECartesian Growth Co. IIN/A0.090.09UPCUniverse PharmaceuticalsN/AN/AN/AVRDNViridian Therapeutics0.0519.4919.49Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipPDPInvesco Dorsey Wright Momentum ETFN/ARENECartesian Growth Co. II58.96%UPCUniverse Pharmaceuticals0.18%VRDNViridian TherapeuticsN/AInsider OwnershipCompanyInsider OwnershipPDPInvesco Dorsey Wright Momentum ETFN/ARENECartesian Growth Co. II26.60%UPCUniverse Pharmaceuticals57.38%VRDNViridian Therapeutics0.65%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionablePDPInvesco Dorsey Wright Momentum ETFN/A15.40 millionN/AOptionableRENECartesian Growth Co. II221.62 million15.87 millionNot OptionableUPCUniverse Pharmaceuticals22043,000731,000Not OptionableVRDNViridian Therapeutics5081.59 million81.06 millionOptionableUPC, VRDN, OBD, PDP, and RENE HeadlinesRecent News About These CompaniesViridian Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)July 3, 2025 | finance.yahoo.comViridian Therapeutics (NASDAQ:VRDN) Shares Down 4.5% - What's Next?June 17, 2025 | marketbeat.comViridian Therapeutics’ SWOT analysis: promising TED treatment stock faces pivotal yearJune 15, 2025 | investing.comViridian Therapeutics, Inc. (NASDAQ:VRDN) Given Consensus Recommendation of "Moderate Buy" by AnalystsJune 12, 2025 | marketbeat.comViridian Therapeutics: The Song Remains The SameJune 9, 2025 | seekingalpha.comUBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Has $2.22 Million Stake in Viridian Therapeutics, Inc. (NASDAQ:VRDN)June 7, 2025 | marketbeat.comViridian Therapeutics to Participate in Upcoming June Investor ConferencesMay 30, 2025 | businesswire.comVeligrotug improves proptosis, diplopia symptoms in active, chronic thyroid eye diseaseMay 22, 2025 | healio.comHViridian Therapeutics’ SWOT analysis: promising TED treatment stock faces key catalystsMay 21, 2025 | investing.comViridian Therapeutics announces positive long-term durability data for veligrotug for the treatment of active thyroid eye diseaseMay 20, 2025 | ophthalmologytimes.comOWhy Viridian Therapeutics, Inc.’s (VRDN) Stock Is Down 5.15%May 15, 2025 | aaii.comAVeligrotug receives breakthrough therapy designation for thyroid eye diseaseMay 9, 2025 | healio.comHViridian Therapeutics Receives FDA Breakthrough Therapy Designation for Veligrotug for the Treatment of Thyroid Eye Disease (TED)May 7, 2025 | finance.yahoo.comViridian Therapeutics shares fall as Q1 loss narrows, revenue beatsMay 6, 2025 | in.investing.comViridian Therapeutics Highlights Recent Progress and Reports First Quarter 2025 Financial ResultsMay 6, 2025 | finance.yahoo.comViridian Therapeutics, Inc. (VRDN) Reports Q1 Loss, Lags Revenue EstimatesMay 6, 2025 | zacks.comWhy Viridian Therapeutics, Inc.’s (VRDN) Stock Is Up 5.71%April 16, 2025 | aaii.comAWhy Viridian Therapeutics, Inc.’s (VRDN) Stock Is Down 6.94%April 9, 2025 | aaii.comAViridian Therapeutics appoints Ajer to its board of directorsApril 8, 2025 | markets.businessinsider.comViridian Therapeutics Appoints Jeff Ajer to its Board of DirectorsApril 7, 2025 | finance.yahoo.comCommit To Buy Viridian Therapeutics At $12.50, Earn 13.2% Annualized Using OptionsMarch 22, 2025 | nasdaq.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesWhy BigBear.ai Could Rally 100% and Catch Palantir SoonBy Gabriel Osorio-Mazilli | June 30, 2025View Why BigBear.ai Could Rally 100% and Catch Palantir SoonIPO Momentum Returns: 3 Stocks Rising After CoreWeave’s SurgeBy Dan Schmidt | June 20, 2025View IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s SurgeBigBear.ai Poised to Benefit as Palantir Dominates AI DefenseBy Gabriel Osorio-Mazilli | June 23, 2025View BigBear.ai Poised to Benefit as Palantir Dominates AI DefenseIntel's Turnaround Strategy Shifts From Planning to Attack ModeBy Jeffrey Neal Johnson | June 20, 2025View Intel's Turnaround Strategy Shifts From Planning to Attack Mode3 Biotech Stocks to Watch: Iovance, Neurocrine & VikingBy Chris Markoch | June 29, 2025View 3 Biotech Stocks to Watch: Iovance, Neurocrine & VikingUPC, VRDN, OBD, PDP, and RENE Company DescriptionsInvesco Dorsey Wright Momentum ETF NASDAQ:PDP$109.09 +1.54 (+1.43%) As of 07/3/2025 01:04 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.PowerShares DWA Technical Leaders Portfolio (the Fund) is based on the Dorsey Wright Technical Leaders Index (the Index). The Fund seeks investment results that generally correspond to the price and yield of the Index. The Fund will normally invest at least 90% of its total assets in securities that consists of the Index and American Depositary Receipts (ADRs) based on the securities in the Index. The Index includes approximately 100 the United States-listed companies. Invesco PowerShares Capital Management LLC acts as the Fund's investment adviser.Cartesian Growth Co. II NASDAQ:RENE$11.75 0.00 (0.00%) As of 05/13/2025Cartesian Growth Corp. II operates as a blank check company. It was formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses. The company was founded on October 13, 2021 and is headquartered in New York, NY.Universe Pharmaceuticals NYSE:UPC$3.85 +0.03 (+0.79%) Closing price 07/3/2025 03:17 PM EasternExtended Trading$3.72 -0.13 (-3.35%) As of 04:01 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Universe Pharmaceuticals INC, through its subsidiaries, engages in the manufacture, marketing, distribution, and sale of traditional Chinese medicine derivative products in China. It offers products for the treatment and relief of common chronic health conditions in the elderly for physical wellness and longevity; and cold and flu medications. The company also distributes and sells third-party products, including biomedical drugs, medical instruments, traditional Chinese medicine pieces, and dietary supplements. Its customers include pharmaceutical companies, hospitals, clinics, and drugstore chains. The company was founded in 1998 and is based in Ji'An, China. Universe Pharmaceuticals INC operates as a subsidiary of Sununion Holding Group Limited.Viridian Therapeutics NASDAQ:VRDN$15.58 +0.36 (+2.33%) Closing price 07/3/2025 01:39 PM EasternExtended Trading$15.58 0.00 (0.00%) As of 07/3/2025 04:20 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Viridian Therapeutics, Inc., a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED. It also provides VRDN-006 a preclinical program for autoimmune disease. In addition, the company offers VRDN-006 and VRDN-008 a preclinical program for autoimmune disease. The company was formerly known as Miragen Therapeutics, Inc. and changed its name to Viridian Therapeutics, Inc. in January 2021.Viridian Therapeutics, Inc. was founded in 2010 and is headquartered in Waltham, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 06/30 - 07/04 The Apple Comeback Will Be Better Than the Setback Micron’s Big Q3 Drives Applied Materials’ Bullish Outlook Correction Equals Opportunity in Domino’s Pizza Stock Why Occidental's Price Dip Signals a Buying Opportunity Qualcomm’s Hold Rating Misses Strong Growth Story Rigetti Computing: Cantor's Bullish Call May Be Just the Start Insider Selling at NVIDIA Could Turn Into an Opportunity Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
